Aduro Biotech, Inc. (NASDAQ:ADRO) COO Gregory W. Schafer sold 4,859 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total value of $53,400.41. Following the sale, the chief operating officer now directly owns 153,604 shares in the company, valued at $1,688,107.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Aduro Biotech, Inc. (ADRO) remained flat at $11.20 during mid-day trading on Friday. 2,170,865 shares of the company were exchanged. Aduro Biotech, Inc. has a 12-month low of $8.75 and a 12-month high of $15.52. The firm’s market capitalization is $835.65 million. The firm has a 50-day moving average price of $11.61 and a 200 day moving average price of $10.97.

Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The business’s revenue for the quarter was down 84.9% on a year-over-year basis. On average, equities research analysts forecast that Aduro Biotech, Inc. will post ($1.37) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Gregory W. Schafer Sells 4,859 Shares of Aduro Biotech, Inc. (ADRO) Stock” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/gregory-w-schafer-sells-4859-shares-of-aduro-biotech-inc-adro-stock.html.

ADRO has been the topic of several analyst reports. HC Wainwright set a $18.00 target price on Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research lowered Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. BidaskClub lowered Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 target price on Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Cowen and Company initiated coverage on Aduro Biotech in a report on Tuesday, July 18th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. Aduro Biotech currently has a consensus rating of “Buy” and an average target price of $19.00.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADRO. Teachers Advisors LLC increased its position in Aduro Biotech by 8.3% during the 4th quarter. Teachers Advisors LLC now owns 60,317 shares of the biotechnology company’s stock worth $688,000 after purchasing an additional 4,625 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Aduro Biotech by 3.8% in the 1st quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after acquiring an additional 5,470 shares during the period. Parametric Portfolio Associates LLC grew its holdings in shares of Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 2,119 shares during the period. Blair William & Co. IL grew its holdings in shares of Aduro Biotech by 0.4% in the 1st quarter. Blair William & Co. IL now owns 189,790 shares of the biotechnology company’s stock worth $2,135,000 after acquiring an additional 735 shares during the period. Finally, American International Group Inc. grew its holdings in shares of Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 1,447 shares during the period. Institutional investors own 35.05% of the company’s stock.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.